Sensus Healthcare (NASDAQ:SRTS) Price Target Raised to $11.00 at HC Wainwright

Sensus Healthcare (NASDAQ:SRTS - Free Report) had its target price raised by HC Wainwright from $10.00 to $11.00 in a report released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Maxim Group boosted their target price on Sensus Healthcare from $12.00 to $14.00 and gave the stock a "buy" rating in a research report on Friday.

Sensus Healthcare Stock Up 10.1 %

NASDAQ SRTS traded up $0.77 on Monday, reaching $8.41. The company had a trading volume of 877,143 shares, compared to its average volume of 278,498. The stock has a market capitalization of $137.83 million, a P/E ratio of 14.60 and a beta of 1.04. The company's fifty day moving average is $6.37 and its 200 day moving average is $5.97. Sensus Healthcare has a 52-week low of $2.02 and a 52-week high of $8.69.

Institutional Investors Weigh In On Sensus Healthcare

Institutional investors have recently added to or reduced their stakes in the company. Hillsdale Investment Management Inc. purchased a new stake in shares of Sensus Healthcare during the first quarter worth about $155,000. Chapin Davis Inc. bought a new stake in shares of Sensus Healthcare in the 2nd quarter worth approximately $53,000. Acadian Asset Management LLC increased its stake in shares of Sensus Healthcare by 578.6% during the second quarter. Acadian Asset Management LLC now owns 45,124 shares of the company's stock valued at $239,000 after buying an additional 38,474 shares during the period. Sachetta LLC raised its holdings in shares of Sensus Healthcare by 12.9% during the second quarter. Sachetta LLC now owns 118,354 shares of the company's stock valued at $631,000 after acquiring an additional 13,544 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Sensus Healthcare by 128.0% in the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company's stock worth $888,000 after acquiring an additional 93,511 shares during the period. Hedge funds and other institutional investors own 25.30% of the company's stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.